These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9177496)

  • 1. 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
    Brain EC; Mita A; Soulié P; Errihani H; Hardy Bessard AC; Chaouche M; Alexandre J; Delord JP; Cvitkovic E; Jasmin C; Misset JL
    J Cancer Res Clin Oncol; 1997; 123(4):227-31. PubMed ID: 9177496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
    Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
    Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A
    Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
    Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
    J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
    Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
    J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
    Bellmunt J; Eres N; Ribas A; Casado S; Albanell J; Baselga J
    Cancer Chemother Pharmacol; 1997; 40(3):273-6. PubMed ID: 9219513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
    Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
    Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
    Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study.
    Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L
    Tumori; 1998; 84(6):659-61. PubMed ID: 10080671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
    Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.